Your browser doesn't support javascript.
loading
Long-term treatment outcomes of acromegaly patients presenting biochemically-uncontrolled at a tertiary pituitary center.
Carmichael, John D; Broder, Michael S; Cherepanov, Dasha; Chang, Eunice; Mamelak, Adam; Said, Qayyim; Neary, Maureen P; Bonert, Vivien.
Affiliation
  • Carmichael JD; Pituitary Center, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA.
  • Broder MS; Partnership for Health Analytic Research, LLC, 280 S. Beverly Dr., Suite 404, Beverly Hills, CA, 90212, USA.
  • Cherepanov D; Partnership for Health Analytic Research, LLC, 280 S. Beverly Dr., Suite 404, Beverly Hills, CA, 90212, USA. dasha@pharllc.com.
  • Chang E; Partnership for Health Analytic Research, LLC, 280 S. Beverly Dr., Suite 404, Beverly Hills, CA, 90212, USA.
  • Mamelak A; Pituitary Center, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA.
  • Said Q; Health Economics and Outcomes Research, Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936, USA.
  • Neary MP; Global Oncology Market Access and Policy, Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936, USA.
  • Bonert V; Pituitary Center, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA.
BMC Endocr Disord ; 17(1): 49, 2017 Aug 04.
Article in En | MEDLINE | ID: mdl-28778166
ABSTRACT

BACKGROUND:

Acromegaly is a rare, slowly progressive disorder resulting from excessive growth hormone (GH) production by a pituitary somatotroph tumor. The objective of this study was to examine acromegaly treatment outcomes during long-term care at a specialized pituitary center in patients presenting with lack of biochemical control.

METHODS:

Data came from an acromegaly registry at the Cedars-Sinai Medical Center Pituitary Center (center). Acromegaly patients included in this study were those who presented biochemically-uncontrolled for care at the center. Biochemical control status, based on serum insulin-like growth factor-1 values, was determined at presentation and at study end. Patient characteristics and acromegaly treatments were reported before and after presentation by presenting treatment status and final biochemical control status. Data on long-term follow-up were recorded from 1985 through June 2013.

RESULTS:

Seventy-four patients presented uncontrolled 40 untreated (54.1%) and 34 (45.9%) previously-treated. Mean (SD) age at diagnosis was 43.2 (14.7); 32 (43.2%) were female patients. Of 65 patients with tumor size information, 59 (90.8%) had macroadenomas. Prior treatments among the 34 previously-treated patients were pituitary surgery alone (47.1%), surgery and medication (41.2%), and medication alone (11.8%). Of the 40 patients without prior treatment, 82.5% achieved control by study end. Of the 34 with prior treatment, 50% achieved control by study end.

CONCLUSIONS:

This observational study shows that treatment outcomes of biochemically-uncontrolled acromegaly patients improve with directed care, particularly for those that initially present untreated. Patients often require multiple modalities of treatment, many of which are offered with the highest quality at specialized pituitary centers. Despite specialized care, some patients were not able to achieve biochemical control with methods of treatment that were available at the time of their treatment, showing the need for additional treatment options.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Pituitary Diseases / Acromegaly / Biomarkers / Adenoma / Human Growth Hormone Type of study: Observational_studies / Prognostic_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: BMC Endocr Disord Year: 2017 Type: Article Affiliation country: United States

Full text: 1 Database: MEDLINE Main subject: Pituitary Diseases / Acromegaly / Biomarkers / Adenoma / Human Growth Hormone Type of study: Observational_studies / Prognostic_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: BMC Endocr Disord Year: 2017 Type: Article Affiliation country: United States